Olsen, Carissa Lynn
UMass Medical School
This proposal explored new drug treatment plans for pancreatic cancer. The mTOR protein kinase activates a signaling network that effects cell growth substantially. Research has shown that unregulated mTOR activity is linked with cancer progression. Therefore, finding inhibitors of mTOR could halter cell growth, particularly those of cancer cells. AZD2014 is a selective inhibitor of the mTOR complex. DNA damage stimulators Doxorubicin, Olaparib, and Trametinib in combination treatments can cause serious cell cycle arrest and death in pancreatic cancer cells. Experiments were completed with pancreatic cancer cells to observe the results of how effective the drug combinations were through p-AKT, total AKT, and Chk-1 signal detection and cell viability.
Worcester Polytechnic Institute
Major Qualifying Project
All authors have granted to WPI a nonexclusive royalty-free license to distribute copies of the work, subject to other agreements. Copyright is held by the author or authors, with all rights reserved, unless otherwise noted.
Chemistry and Biochemistry